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A range of pentafluorophenyl (PFP) sulfonate esters derived 
from the reaction of PFP vinyl sulfonate and various nitrones are 
shown to have significant inhibitory activity against the bacterial 
enzymes DDAH and ADI. 
Nitric oxide (NO) is an important mediator of intracellular 
signaling and has attracted interest as a target for therapeutic 
intervention, as it is widely acknowledged that there are a variety 
of disease states for which NO is implicated.1 One of the most 
significant problems associated with the design of inhibitors, is to 
target the pathological excess NO production without disrupting 
essential NO-mediated processes, often by seeking selectivity for 
a particular NOS isoform. One method for potentially 
circumventing these problems is the indirect modulation of NO 
levels by inhibition of the enzyme DDAH which is responsible 
for controlling levels of NG-methyl-L-arginine (MMA) and NG, 
NG, dimethyl-L-arginine (ADMA) which are endogeneous 
inhibitors of NOS.2,3 
Inhibition of bacterial DDAH4 is also of interest as it offers 
opportunities for the development of new anti-bacterial agents. 
The structurally related enzyme arginine deiminase (ADI) is also 
a possible antibacterial/antiprotozoal target, as various pathogenic 
organisms utilize ADI to generate ATP under anaerobic 
conditions.5a  
Recently high-resolution structures of a bacterial DDAH6 and 
ADI5 have been disclosed and it has been shown in both enzymes 
that the active site comprises a catalytic triad containing an acidic 
residue (Glu / Asp), a basic residue (His) and a cysteine residue 
(Cys) (Figure 1). Both enzymes are known to catalyze the 
conversion of the substrate(s) MMA and ADMA to citrulline as 
shown in figure 1. 
 
 
 
Figure 1: Conversion of ADMA (R = Me) and / or MMA (R = H) to 
citrulline are  catalysed by DDAH and ADI. 
In a recent communication Knipp et al. described the cysteine 
modification of DDAH by HcyNO and proposed this as a lead for 
the possible development of covalent inhibitors of DDAH and 
ADI.7 In that work it was proposed that it should be possible to 
rationally design covalent inhibitors of DDAH based on those 
findings. That work has prompted us to disclose our own studies, 
which identify novel small molecule inhibitors of DDAH and 
ADI.  Whilst the development of small molecule inhibitors of 
both DDAH and ADI is appealing, it is notable that there is only 
one known inhibitor of bacterial DDAH, which has modest 
affinity and is an arginine homologue,8 and there are no known 
inhibitors of ADI. Herein we disclose our preliminary studies on 
the use of pentafluorophenyl (PFP) sulfonates as an 
unprecedented new class of enzyme inhibitors. The biological 
activity of the PFP-sulfonate group is completely unexplored and 
is highlighted here by the development of inhibitors of DDAH 
and ADI  
As had previously been noted by one of us in the disclosure of 
the crystal structure of DDAH, the active site resembles that of a 
cysteine protease with a catalytic triad (Fig 1).5  
The work of Roush et al. on the use of sulfonates and 
sulfonamides as inhibitors of cysteine proteases,9 stimulated us to 
speculate that it may be possible to generate inhibitors of DDAH 
and ADI based on sulfonates and sulfonamides or closely related 
structures. This would offer an opportunity to develop molecular 
scaffolds, which would be markedly different in their structure to 
arginine mimetics, which may be a more obvious class of 
potential inhibitor. In order to test this speculative hypothesis we 
decided to evaluate a diverse collection of heterocyclic PFP-
sulfonates as potential inhibitors of DDAH and ADI. 
Our previously disclosed synthetic approach to such species 
was based on the 1,3-dipolar cycloaddition reaction of a PFP-
sulfonate with nitrones (Scheme 1).10 
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Scheme 1. Synthetic approach to heterocyclic PFP-sulfonates via 1,3-
dipolar cycloaddition 
An initial screen of a variety of PFP-sulfonates and related 
structures at relatively high concentrations (500 µm, data not 
shown) provided some encouraging inhibition of both 
pseudomonas
80 
85 
90 
 enzymes DDAH and ADI. At 50 µm a smaller 
selection of PFP sulfonates retained significant activity and their 
molecular structures are shown in Figure 2.  
As can be seen from Table 1 the majority of these compounds 
were found to have activity against both DDAH and ADI at 50 
µm concentration. These preliminary data indicate that there is 
greater inhibition of DDAH compared with ADI. IC50 values 
were determined for a small selection of the most active species 
and it can be seen that compounds 2, 3, 4, 6 and 9 exhibit 
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significant activity against DDAH and compounds 3 and 6 also 
show significant activity against ADI. 
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Figure 2: Molecular structures of PFP sulfonates exhibiting significant 
inhibition of PaDDAH and PaADI 95 
100 
These data suggest that there is potential for considerable 
optimization to give a new series of inhibitors based on the PFP-
isoxazolidine structural motif. 
Table 1.  Activity of PFP-sulfonates against PaDDAH and PaADI (1mM 
substrate) 
Entry 
DDAH 
Inhibition 
at 50 µM 
IC50 / 
DDAH, 
µM 
ADI 
Inhibition at 
50 µM 
IC50 / 
ADI, 
µM 
1 30% - 14% - 
2 63% 34 27% 246 
3 76% 21 35% 74 
4 56% 32 33% 167 
5 40% - 26% - 
6 65% 16 38% 103 
7 44% - 14% - 
8 41% - 15% - 
9 58% 58 27% - 
In order to assess the nature of the inhibition we carried out 
experiments on reversibility and time-dependence (Figure 3). 
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Figure 3.  (a) Effect of increasing substrate concentration on inhibition of 
PaDDAH by compound 6, 75µM. (b) Time-dependence of PaDDAH 
inhibition by compound 3, 10µM.
 
Inhibition by compound 6 can be at least partially reversed by  
addition of increased amounts of substrate (Figure 3a), suggesting 
competitive inhibition. The large excess of substrate required to 
reverse inhibition may indicate that the inhibitor is more tightly 
bound than the substrate.  In a separate experiment, compound 3 
exhibited a constant level of DDAH  
inhibition over an 80-minute period (Figure 3b). Covalent 
inhibitors would show a time-dependent increase in inhibition as 
the enzyme becomes progressively irreversibly bound, therefore 
the evidence suggests that our inhibitors are not acting by a 
covalent mechanism.  This is consistent with the observed 
reversibility of inhibition.11
In summary we have described new inhibitors of the enzymes 
DDAH and ADI. From these experiments it would appear that 
these PFP-sulfonates may be reversible inhibitors of DDAH. 
Irrespective of the detailed mechanism underlying the inhibition, 
this is the first time that non-substrate-like inhibitors for DDAH 
have been identified and these are the most potent inhibitors of 
bacterial DDAH currently known. Moreover these results identify 
the first small molecules to inhibit the enzyme ADI. The present 
study has also demonstrated that the PFP-sulfonate motif may 
play an important role in future studies directed toward 
identification of small molecule enzyme inhibitors and / or 
ligands for proteins. The simplicity with which diverse arrays of 
PFP-derivatives can be prepared may facilitate further small-
molecule discovery activities. The further development of this 
work to identify details of the molecular interaction of these PFP-
sulfonate derivatives with DDAH and ADI are underway. 
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